Conference Reports for NATAP
The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025
Back
Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis
AASD 2025 Nov 7-11 Wash DC
Cynthia Levy
